Evidence map›Paper›PMID 35274188›Full record

SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer.

Ainhoa Madariaga, Jenny Lau, Arunangshu Ghoshal, Tomasz Dzierżanowski, Philip Larkin, Jacek Sobocki, Andrew Dickman, Kate Furness, Rouhi Fazelzad, Gregory B Crawford and 1 more

Registry-linked trialOpen access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04840264 (A Multi-center, Non-randomized, Three-cohort, Phase II Trial of a Modified Triplet Combination of Docetaxel, Oxaliplatin and Fluorouracil for Gastric Cancer With Peritoneal Carcinomatosis and Inoperable Malignant Bowel Obstruction), which is not on this map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
11.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04840264 phase2recruitingnot on this map

A Multi-center, Non-randomized, Three-cohort, Phase II Trial of a Modified Triplet Combination of Docetaxel, Oxaliplatin and Fluorouracil for Gastric Cancer With Peritoneal Carcinomatosis and Inoperable Malignant Bowel Obstruction

TypeinterventionalSponsorSixth Affiliated Hospital, Sun Yat-sen UniversityRan2022 to 2028Enrolled79ConditionsMetastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Peritoneal CarcinomatosisArmsDocetaxel, Oxaliplatin, Fluorouracil
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Contemporary Management of Malignant Bowel Obstruction.Clinics in colon and rectal surgery · 2025
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 6 countries.

Ainhoa MadariagaDepartment of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Jenny LauDepartment of Supportive Care, Princess Margaret Cancer Centre, Toronto, Canada.
Arunangshu GhoshalDepartment of Supportive Care, Princess Margaret Cancer Centre, Toronto, Canada.
Tomasz DzierżanowskiLaboratory of Palliative Medicine, Department of Social Medicine and Public Health, Medical University of Warsaw, Warsaw, Poland.
Philip LarkinPalliative and Supportive Care Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Jacek SobockiDepartment of General Surgery and Clinical Nutrition, Centre for Postgraduate Medical Education, Warsaw, Poland.
Andrew DickmanAcademic Palliative and End of Life Care Department, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, England, UK.
Kate FurnessDepartment of Dietetics, School of Health Sciences, Swinburne University of Technology, Hawthorn, Victoria, Australia.
Rouhi FazelzadLibrary and information services, University of Health Network, Toronto, Canada.
Gregory B CrawfordNorthern Adelaide Palliative Service, Northern Adelaide Local Health Network, Adelaide, Australia.
Stephanie LheureuxDepartment of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada. stephanie.lheureux@uhn.ca.
Princess Margaret Cancer Centre · CAMedical University of Warsaw · PLPostgraduate School of Molecular Medicine · PLRoyal Liverpool and Broadgreen University Hospital NHS Trust · GBSwinburne University of Technology · AUUniversity Health Network · CAUniversity of Adelaide · AUUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo provide evidence-based recommendations on the management of malignant bowel obstruction (MBO) for patients with advanced cancer.

methodsThe Multinational Association for Supportive Care in Cancer (MASCC) MBO study group conducted a systematic review of databases (inception to March 2021) to identify studies about patients with advanced cancer and MBO that reported on the following outcomes: symptom management, bowel obstruction resolution, prognosis, overall survival, and quality of life. The review was restricted to studies published in English, but no restrictions were placed on publication year, country, and study type. As per the MASCC Guidelines Policy, the findings were synthesized to determine the levels of evidence to support each MBO intervention and, ultimately, the graded recommendations and suggestions.

resultsThe systematic review identified 17,656 published studies and 397 selected for the guidelines. The MASCC study group developed a total of 25 evidence-based suggestions and recommendations about the management of MBO-related nausea and vomiting, bowel movements, pain, inflammation, bowel decompression, and nutrition. Expert consensus-based guidance about advanced care planning and psychosocial support is also provided.

conclusionThis MASCC Guideline provides comprehensive, evidence-based recommendations about MBO management for patients with advanced cancer.

Indexed as

Intestinal ObstructionNeoplasmsHumansNauseaPalliative CareQuality of LifeCancer—gastrointestinalGuidelinesGynecologic neoplasmMalignant bowel obstructionPalliative Care

Identifiers

PMID35274188
PMCPMC9046338
OpenAlexW4220795868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.